- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Targeting epigenetics in sarcomas through EZH2 inhibition ; volume:13 ; number:1 ; day:7 ; month:4 ; year:2020 ; pages:1-3 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (7.4.2020), 1-3, 12.2020
- Creator
-
Italiano, Antoine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-00868-4
- URN
-
urn:nbn:de:101:1-2020062323071390496920
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Italiano, Antoine
- SpringerLink (Online service)
Other Objects (12)
Targeting epigenetics for cancer therapy
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands
Pharmacological inhibition of EZH2 disrupts the female germline epigenome
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs
Epigenetics
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma
EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma
Targeting epigenetics for cancer therapy
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands
Pharmacological inhibition of EZH2 disrupts the female germline epigenome
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs
Epigenetics
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma
EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma
Targeting epigenetics for cancer therapy
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands
Pharmacological inhibition of EZH2 disrupts the female germline epigenome
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs
Epigenetics
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma